Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China-Reference-Cited by-同舟云学术

Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China

Published:2020-04-26 Issue:3 Volume:20 Page:313-320
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Yi Zhan-Miao¹²³^ORCID,Men Peng¹³,Qu Shuli⁴^ORCID,Li Chaoyun⁵,Yu Xin⁶,Zhai Suodi¹³

Affiliation:

1. Department of Pharmacy, Peking University Third Hospital, Beijing, China

2. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China

3. Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China

4. Real-World Insights, IQVIA, Shanghai, China

5. Health Economics & Outcome Research, Sanofi, Shanghai, China

6. Department of Psychiatry, Peking University Sixth Hospital, Beijing, China

Funder

Sanofi China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2020.1752670

Reference39 articles.

1. Schizophrenia

2. Social functioning and the quality of life of patients diagnosed with schizophrenia

3. The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010

4. WHO. The global burden of disease: 2004 update. WHO; 2018 [cited 2019 Sep 10] Available from: https://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/.

5. The Cost of Relapse in Schizophrenia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia;Frontiers in Public Health;2021-10-20